You are here

AVAC's Blog: P-Values

The 3Ps for Prevention (Partners, Perceptions and Pills) study (3P) on PrEP use among adolescent girls and young women incorporated a photography project as a way for the young women to document their experience with PrEP. The images they created gave researchers a unique view into participants’ perspectives on PrEP, revealing new dimensions to their experience and the factors that encourage or discourage PrEP use.

In this unprecedented time, AVAC has been urgently gathering evidence-based information on COVID-19 and the research underway to treat or prevent it. We are sharing these resources with you today—scroll down to dig in immediately.

Advocacy organizations around the world have initiated a call for ethical research for COVID-19 solutions asking for treatment and prevention options around the globe along with ethical and inclusive R&D to meet this critical need.

There’s much we do and don’t know about COVID-19 and the virus that causes it. The global response to COVID-19, which is evolving rapidly, can and must benefit from lessons learned in the fight against HIV. AVAC is committed to data-driven, evidence-based advocacy, and we hope these resources help us all stay up-to-date on the facts, share experiences and make sure interventions for COVID-19 and HIV reach those who need them the most.

It is with an incredibly heavy heart that we mourn the passing of Gita Ramjee on Tuesday, March 30 of COVID-19 related complications. She was a great friend to AVAC over the years – and she was an essential partner in helping to navigate the field through more disappointing results than any of us wanted. But those results never deterred her tireless determination to keep pushing for the next trial. Gita will be sorely missed by all of us who had the privilege to work with her. May we all build on her legacy and make her calling, her dream a reality.

Many of us are focused on the global—and in most cases very personal—response to the COVID-19 pandemic, but the work in the fight against HIV continues apace. In this update, AVAC shares the essential work of civil society groups and activists who are influencing PEPFAR programming for the coming year. Their continuing advocacy led to important wins, gained over the three weeks spent at the Regional Planning Meetings (RPMs) in Johannesburg.

In the second installment of AVAC’s webinar series on COVID-19 and its relationship to HIV, Dr. Mark Feinberg, CEO of IAVI, shared experiences and lessons from Ebola and HIV vaccine development that might be applied to COVID-19 vaccine development. Dr. Feinberg was joined by Dr. Helen Rees of Wits RHI to discuss the history and role of the Coalition for Epidemic Preparedness Innovations (CEPI), which supports vaccine development against emerging infectious diseases, including COVID-19.

AVAC is committed to data-driven, evidence-based advocacy, and we hope these resources help us all stay up-to-date on the facts, share experiences and make sure interventions for COVID-19 and HIV reach those who need them the most.